Company news
Acrux Limited (ASX:ACR) news
Acrux Limited news releases on 6ix. Latest, Nov 8, 2023: Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
Press releases — page 2
Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
November 7, 2023
Investor Presentation - Acrux FY23 Results
August 24, 2023
Appendix 4E and FY23 Annual Report
August 24, 2023
Activities Statement and Appendix 4C
July 26, 2023
Acruxs seventh generic dossier accepted by FDA for review
July 3, 2023
4th FDA ANDA approval received - Dapsone Gel, 5%
June 7, 2023
Appendix 4D and Half Year Report
February 23, 2023
Quarterly Activities / Appendix 4C Cashflow Report
January 29, 2023
Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
January 22, 2023
Launch of prilocaine and lidocaine cream in United States
December 20, 2022
Mutual Termination of Co-Development Agreement
December 15, 2022
Chairman and CEO address to AGM
November 22, 2022
Remaining balance of R&D Tax Incentive Rebate received
October 2, 2022
Appendix 4E and FY22 Annual Report
August 25, 2022
Acruxs sixth generic dossier accepted by FDA for review
August 7, 2022
Acrux announces commercial agreement with Padagis
June 20, 2022
Successful patent litigation outcome
May 29, 2022
Appendix 4D, Half Year Accounts as at 31 December 2021
February 24, 2022
Acrux and Harris terminate license agreement
October 10, 2021
Acruxs fifth generic dossier accepted by FDA for review
September 12, 2021
Acrux Investor Presentation - September 2021
September 1, 2021
US Launch - Testosterone Topical Solution
August 25, 2021
Appendix 4E and Financial Report
August 25, 2021
Acrux receives third FDA ANDA approval
July 27, 2021
Acrux Receives FDA Approval - Generic Efinaconazole Solution
June 22, 2021
Acrux confirms patent challenge
June 7, 2021
Acruxs fourth generic dossier accepted by FDA for review
April 15, 2021
Acrux Investor Presentation
February 24, 2021
Appendix 4D and Half Year Accounts - for the 31 Dec ac
February 24, 2021
Share Purchase Plan Closes Oversubscribed
February 2, 2021
Acrux Receives FDA Approval - Generic Testosterone Solution
January 11, 2021
Acrux Ltd Share Purchase Plan Offer Booklet
January 7, 2021
Acrux Raises $7.8m Via Placement and Announces SPP
December 20, 2020
Acrux Signs Licensing Agreement with Dash Pharmaceuticals
October 11, 2020
Appendix 4E and Full Year Statutory Accounts
August 24, 2020
Acrux Signs Licensing Agreement with Harris Pharmaceutical
August 10, 2020
Acrux Signs Co-Development Agreement With Amring
June 17, 2020
Acrux Signs Licensing Agreement With TruPharma
May 28, 2020
Appendix 4D and Half Year Financial Report
February 25, 2020
Receipt of first R&D Tax Incentive Rebate
October 24, 2019
Acrux Ltd Investor Presentation and Full Year Results
August 26, 2019
Appendix 4E & Full Year Statutory Accounts
August 23, 2019
Jublia Patent Litigation Settlement
April 3, 2019
Appendix 4D and Half-Year Financial Report to 31 Dec 2018
February 21, 2019
Acrux Receives $2.057m R&D Tax Incentive Rebate
January 21, 2019
Acrux has second generic dossier accepted for review by FDA
October 16, 2018
Acrux confirms patent challenge for generic of efinaconazole
September 23, 2018
Appendix 4E and 2018 Financial Report
August 16, 2018
Acrux Submits First-To-File Generic of Jublia
August 2, 2018
Appendix 4D and Half-Year Report to 31 December 2017
February 20, 2018